Literature DB >> 6323295

Changes in the status of neurotransmitter receptors in a rabbit model of hepatic encephalopathy.

P Ferenci, S C Pappas, P J Munson, K Henson, E A Jones.   

Abstract

It has previously been shown in an animal model of hepatic encephalopathy (HE) that the number of receptors for the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), increases and that the number of receptors for the excitatory neurotransmitter, glutamate, decreases. To determine the functional status of other neurotransmitter systems in HE, measurements were made of the specific binding of other neurotransmitters to synaptic membranes prepared from the brains of normal rabbits and rabbits in HE due to galactosamine-induced acute liver failure. The development of HE was associated with: (i) a decrease in the density (Bmax) of receptors for the two excitatory amino acid neurotransmitters, aspartate and kainic acid; (ii) an increase in the Bmax of both the low and high affinity binding site for strychnine, a marker for the inhibitory neurotransmitter glycine; (iii) a decrease in the affinity (Kd) of receptors for dopamine, and (iv) no appreciable change in either the specific binding of [3H]D-ala2-methionine enkephalinamide or [3H]naloxone, markers for opiate receptors, or in the Bmax or the Kd of receptors for acetylcholine. If it is assumed that the sensitivity of the brain to neurotransmitters varies directly with the density of neurotransmitter receptors, HE may be associated with increased sensitivity to inhibitory amino acid neurotransmitters and decreased sensitivity to excitatory amino acid neurotransmitters. Thus, the observed changes in neurotransmitter receptors in HE afford a feasible pathophysiological basis for the mediation of the neural inhibition of HE.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323295     DOI: 10.1002/hep.1840040204

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

Review 1.  Animal models of acute hepatic failure.

Authors:  T M Rahman; H J Hodgson
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Regional glycine receptor binding in the p,p'-DDT myoclonic rat model.

Authors:  M R Pranzatelli; K Tkach
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

Review 3.  Glutamatergic synaptic dysfunction in hyperammonemic syndromes.

Authors:  V L Rao; C R Murthy; R F Butterworth
Journal:  Metab Brain Dis       Date:  1992-03       Impact factor: 3.584

Review 4.  EEG and event related potentials in hepatic encephalopathy.

Authors:  M G Davies; M J Rowan; J Feely
Journal:  Metab Brain Dis       Date:  1991-12       Impact factor: 3.584

5.  Inhibitory neuromodulators do not alter the course of experimental hepatic encephalopathy.

Authors:  D Rzepczynski; L Zieve; S Lindblad
Journal:  Metab Brain Dis       Date:  1988-09       Impact factor: 3.584

6.  Cortical benzodiazepine receptor binding in a rabbit model of hepatic encephalopathy: the effect of Triton X-100 on receptor solubilization.

Authors:  M Rössle; K D Mullen; E A Jones
Journal:  Metab Brain Dis       Date:  1989-09       Impact factor: 3.584

7.  Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate receptor during experimental encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit.

Authors:  R J de Knegt; J Kornhuber; S W Schalm; K Rusche; P Riederer; J Tan
Journal:  Metab Brain Dis       Date:  1993-06       Impact factor: 3.584

8.  CNQX binding to non-NMDA glutamate receptors in canine cerebro-cortical crude synaptosomal membranes: pharmacological characterization and comparison of binding parameters in dogs with congenital portosystemic encephalopathy and control dogs.

Authors:  J E Maddison; W E Watson; G A Johnston
Journal:  Metab Brain Dis       Date:  1992-03       Impact factor: 3.584

Review 9.  The use of sedative agents in critically ill patients.

Authors:  A M Burns; M P Shelly; G R Park
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

10.  A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding.

Authors:  L Zieve; P Ferenci; D Rzepczynski; J Ebner; C Zimmermann
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.